TickerTalks
Browse all tickers →
TickerTalks›$TECH
TETECH

Bio-Techne Corporation

$TECH·$11B·Biotechnology·Healthcare
$72.61+0.1%YTD+23.3%1Y+43.8%
Price updated 2d ago·X counts updated 14d ago
TETECH
$TECHBio-Techne Corporation
$72.61+0.06%62 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $TECH on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

62X posts · last 7 days
Sep 9Sep 13
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $TECH's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data14 posts analyzed · as of 2026-07-02

Bio-Techne merger arbitrage attractive spread as long as it doesn't drag beyond 2026. Sentiment leans bullish.

Read what X is saying about $TECH

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TECH — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-26

The move is getting stronger, with heavier trading behind it.

Life-sciences tools company with Merck KGaA acquisition approved by shareholders.

Bio-Techne is a life-science reagents-and-instruments supplier for research, diagnostics and bioprocessing, and the accelerating chip fits — 99.7% of the 52-week range (essentially at the annual high), +0.6% versus the 50-day, +17.7% versus the 200-day, up 44% over twelve months.

  • Trailing P/E of 99.6, price-to-sales 9.14, EV/EBITDA 43.2, ROIC 4.7%, ROE 5.5%, gross margin 64.9%, operating margin 12.7%, debt-to-equity 0.14, FCF yield 2.4% — premium life-sciences multiples, though the deal-price arbitrage sets the ceiling.
  • Q3 FY26 revenue was $311M, down 1.5% year-over-year (a modest revenue reset), with gross margin 66.9%; the last four EPS surprises are +0.2%, -3.6%, +7.0%, -0.3% — a consensus-tracking pattern with the recent print essentially flat.
  • Robert V. Baumgartner (director) executed a paired M-Exempt (option exercise) of 31,880 shares at $12.65 and F-InKind (tax-withhold on vesting) of 5,559 shares at $72.55 for $403K on 2026-09-22 — non-directional. Load-bearing filings: shareholders approved the pending acquisition by Merck KGaA, with a definitive proxy filed 2026-08-20; a Düsseldorf Customer Experience Center opened.

Accelerating into the 2026-11-04 Q1 FY27 print — the equity is now trading on the Merck KGaA deal-close spread; any commentary on integration timeline and any closing risk from the shareholder-vote merger process are the swings; standalone operating results matter less until close.

Differs from X sentimentNo X chatter in the window; the Merck KGaA deal-approval headline dominates and defines the near-term optionality.

What to watch: Q1 FY27 print 2026-11-04 for Merck KGaA integration commentary and any closing-risk flags.

On the calendar: 2026-11-04 — FQ1 FY27 earnings (consensus $0.46 EPS)

Read the AI verdict on $TECH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Life science company manufacturing research reagents, recombinant proteins, and spatial biology diagnostics for pharma R&D and bioprocessing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TECH.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

What this means for $TECH

Partial — Bio-Techne sells research tools (cytokines, proteins, immunoassays) for biotech R&D; rising biotech R&D investment in oncology and cell therapy increases consumable demand; indirect but durable beneficiary through instrument and reagent spend.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.6%YTD
+50.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
99.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
4.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
12.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
5.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
65.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$0.52$0.52+0.2%
Q1 2026May 6, 2026$0.53$0.55-3.6%
Q4 2025Feb 4, 2026$0.46$0.43+7.0%
Q3 2025Nov 5, 2025$0.42$0.42-0.3%
Next earningsWed, Nov 4·consensus EPS $0.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$311.4M-1.5%66.9%24.2%$0.33$77.6M
Q2 FY26$295.9M-0.4%64.6%18.4%$0.24$76.5M
Q1 FY26$286.6M-1.0%65.6%16.6%$0.25$22.2M
Q4 FY25$317.0M+3.5%62.7%-7.5%$-0.11$93.3M

Forward consensus

6-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.2B$1.2B – $1.2B$1.92$1.87 – $1.9511
FY27$1.3B$1.2B – $1.3B$2.05$1.98 – $2.1211
FY28$1.4B$1.4B – $1.4B$2.34$2.25 – $2.437
FY29$1.6B$1.5B – $1.7B$2.68$2.59 – $2.824
FY30$1.7B$1.7B – $1.8B$2.46$2.38 – $2.592
FY31$2.0B$1.9B – $2.0B$0.00$0.00 – $0.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+17.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 155.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.275-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 8Amy E. HerrDirector6.6K sh$320K
+ 49 other (20 exempts · 19 inkinds · 6 awards · 4 returns) in window

See when $TECH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 268-K — Item 1.01: Material agreement · Item 5.02: Officer or director change
AI summary

Bio-Techne Corporation entered into an Agreement and Plan of Merger on June 25, 2026 with Merck KGaA (Germany) and its wholly-owned subsidiary EMD Holdings NewCo, Inc. (Minnesota), under which Merck KGaA will acquire Bio-Techne in a cash merger. Each outstanding share of Bio-Techne common stock will be converted into the right to receive $73.00 in cash at closing; the Bio-Techne board unanimously approved and declared the deal advisable. This is a transformative take-private acquisition — at $73.00 per share, it will return all capital to public shareholders and remove TECH from public markets upon completion.

8-KPress release / Reg FDJun 258-K — Item 7.01: Press release / Reg FD
AI summary

Bio-Techne Corporation and Merck KGaA jointly issued a press release on June 25, 2026 via a Reg FD 8-K confirming the execution of an Agreement and Plan of Merger under which Merck KGaA will acquire Bio-Techne. This filing is a companion disclosure to the Item 1.01 8-K filed the same day and introduces no additional terms beyond the merger announcement. Supplementary announcement filing — see the Item 1.01 filing for the full merger agreement details including $73.00 per share cash consideration.

+ 17 other (7 proxys · 3 13Gs · 2 8-Ks · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germanyprnewswire.com·4d agoBio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaborationprnewswire.com·5d agoWhy Is Techne (TECH) Down 0.1% Since Last Earnings Report?zacks.com·16d ago$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBANgurufocus.com·17d agoCMB.TECH: Updates From Our Top Shipping Pick Of 2026seekingalpha.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $TECH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport